Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05392699 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

ABOD2011 in Patients With Advanced Solid Tumors Progressed After Standard Systemic Therapy

StatusCompleted
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial completed Final enrollment: 20 participants (planned 60) · Primary completion date changed from estimate of Mar 2025 to Dec 9, 2023 · Eligibility criteria expanded, about 22 words · 1 more Show 4 more changesShow less
    • Final enrollment: 20 participants (planned 60)
    • Primary completion date changed from estimate of Mar 2025 to Dec 9, 2023
    • Eligibility criteria expanded, about 22 words
    • Site details revised
  2. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of May 2022 to May 25, 2022 · Site details revisedv2 Show 2 more changesShow less
    • Start date changed from estimate of May 2022 to May 25, 2022
    • Site details revised
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Based on the activation and regulation of immune system by cytokines, mRNA encoding cytokines has become one of the important directions of mRNA tumor drug development. This product (ABOD2011) is a new generation mRNA product for intratumoral injection. The primary objective of this study is to assess the safety and tolerability, of ABOD2011 in patients with advanced solid tumors that progressed after standard systemic therapy.
Trial Details
NCT Number NCT05392699
Lead Sponsor Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Conditions Patients With Advanced Solid Tumors
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov